Cargando…

Chromogranin A, a significant prognostic factor in small cell lung cancer

Chromogranin A (CgA) is a protein present in neuroendocrine vesicles. Small cell lung cancer (SCLC) is considered a neuroendocrine tumour. It is possible to demonstrate CgA expression in SCLC by immunohistochemical methods. Since CgA is released to the circulation it might also work as a clinical tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Drivsholm, L, Paloheimo, L I, Østerlind, K
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362890/
https://www.ncbi.nlm.nih.gov/pubmed/10574253
http://dx.doi.org/10.1038/sj.bjc.6690745
_version_ 1782153566881841152
author Drivsholm, L
Paloheimo, L I
Østerlind, K
author_facet Drivsholm, L
Paloheimo, L I
Østerlind, K
author_sort Drivsholm, L
collection PubMed
description Chromogranin A (CgA) is a protein present in neuroendocrine vesicles. Small cell lung cancer (SCLC) is considered a neuroendocrine tumour. It is possible to demonstrate CgA expression in SCLC by immunohistochemical methods. Since CgA is released to the circulation it might also work as a clinical tumour marker. We used a newly developed two-site enzyme-linked immunosorbent assay for CgA in plasma from 150 newly diagnosed patients with SCLC. Follow-up was for a minimum of 5 years. Thirty-seven per cent of the patients had elevated pretreatment values and the values were significantly related to stage of disease. Multivariable analysis by Cox's proportional hazard model including nine known prognostic factors disclosed performance status as the most influential prognostic factor followed by stage of disease, CgA and LDH. A simple prognostic index (PI) could be established based on these four pretreatment features. In this way the patients could be separated into three groups with significant different prognosis. The median survival and 95% confidence intervals for the three groups were as follows: 424 days (311–537), 360 days (261–459) and 174 days (105–243). © 1999 Cancer Research Campaign
format Text
id pubmed-2362890
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23628902009-09-10 Chromogranin A, a significant prognostic factor in small cell lung cancer Drivsholm, L Paloheimo, L I Østerlind, K Br J Cancer Regular Article Chromogranin A (CgA) is a protein present in neuroendocrine vesicles. Small cell lung cancer (SCLC) is considered a neuroendocrine tumour. It is possible to demonstrate CgA expression in SCLC by immunohistochemical methods. Since CgA is released to the circulation it might also work as a clinical tumour marker. We used a newly developed two-site enzyme-linked immunosorbent assay for CgA in plasma from 150 newly diagnosed patients with SCLC. Follow-up was for a minimum of 5 years. Thirty-seven per cent of the patients had elevated pretreatment values and the values were significantly related to stage of disease. Multivariable analysis by Cox's proportional hazard model including nine known prognostic factors disclosed performance status as the most influential prognostic factor followed by stage of disease, CgA and LDH. A simple prognostic index (PI) could be established based on these four pretreatment features. In this way the patients could be separated into three groups with significant different prognosis. The median survival and 95% confidence intervals for the three groups were as follows: 424 days (311–537), 360 days (261–459) and 174 days (105–243). © 1999 Cancer Research Campaign Nature Publishing Group 1999-10 /pmc/articles/PMC2362890/ /pubmed/10574253 http://dx.doi.org/10.1038/sj.bjc.6690745 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Drivsholm, L
Paloheimo, L I
Østerlind, K
Chromogranin A, a significant prognostic factor in small cell lung cancer
title Chromogranin A, a significant prognostic factor in small cell lung cancer
title_full Chromogranin A, a significant prognostic factor in small cell lung cancer
title_fullStr Chromogranin A, a significant prognostic factor in small cell lung cancer
title_full_unstemmed Chromogranin A, a significant prognostic factor in small cell lung cancer
title_short Chromogranin A, a significant prognostic factor in small cell lung cancer
title_sort chromogranin a, a significant prognostic factor in small cell lung cancer
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362890/
https://www.ncbi.nlm.nih.gov/pubmed/10574253
http://dx.doi.org/10.1038/sj.bjc.6690745
work_keys_str_mv AT drivsholml chromograninaasignificantprognosticfactorinsmallcelllungcancer
AT paloheimoli chromograninaasignificantprognosticfactorinsmallcelllungcancer
AT østerlindk chromograninaasignificantprognosticfactorinsmallcelllungcancer